Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
09/2000
09/06/2000CN1265647A Acrylic metalloprotease inhibitor
09/06/2000CN1265645A Urokinase inhibitors
09/06/2000CN1265591A Coumpound
09/06/2000CN1265590A Substituted alkanohydroxamic acid and method of reducing TNF 'alpha' levels
09/06/2000CN1265585A (Imidazol-5-yl) methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation
09/06/2000CN1265307A Application of two kinds of cationic dye mixture in direct dyeing of keratin fiber
09/06/2000CN1056144C New use of 6-heterocyclic-4-amino-3,4,5-tetrahydrobenz (CD) indoles compound
09/06/2000CN1056143C Piperidine derivatives and its use
09/06/2000CN1056141C 哌嗪衍生物 Piperazine derivatives
09/06/2000CN1056140C Biphenyl derivatives, their preparation and theirt use for treatment of hypertension and cardiac disease
09/06/2000CN1056083C Method and compositions for treatment and repair of defects or lesions in cartilage
09/06/2000CN1056073C Nutritious health-care oral liquor
09/06/2000CN1056072C Vaginal cleaning powder
09/06/2000CN1056067C Wuji (black-bone chicken) tonic liquid
09/06/2000CN1056057C Pharmaceutical compositions permitting the prolonged release of trimetazidine after oral administraion
09/05/2000US6114568 Process for alkylating hindered sulfonamides useful in the production of matrix metalloproteinase inhibitors
09/05/2000US6114545 Inhibitors of cholesterol esterase
09/05/2000US6114537 Process for scavenging thiols
09/05/2000US6114533 2,4-pentadienoic acid derivatives having retinoid-like biological activity
09/05/2000US6114520 5'-deoxy-cytidine derivatives
09/05/2000US6114515 PIGRL-1, a member of immunoglobulin gene superfamily
09/05/2000US6114395 Method of treating atherosclerosis
09/05/2000US6114394 Protecting mammalian cells from harmful cellular effects caused by exposure to ionizing radiation
09/05/2000US6114393 Use of inhibitors of the sodium-hydrogen exchanger for the production of a pharmaceutical for the treatment of disorders which are caused by protozoa
09/05/2000US6114385 Administering l-carnitine, acyl l-carnitine derivatives or pharmacologically acceptable salts thereof for prophylaxis of diseases or treatment of cellular disorders caused by high levels of ceramide
09/05/2000US6114372 Matrix metalloproteinase (mmp); tumor necrosis factor(tnf); compounds such as n2-((2s)-acetylmercapto)acetyl-5-phthalimidopentanoyl)-n1-((4 -methoxybenzene)sulphonyl)-n1-(phenylmethyl)hydrazine
09/05/2000US6114361 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
09/05/2000US6114360 Pyrrole compounds
09/05/2000US6114359 Endothelin receptor antagonists
09/05/2000US6114346 Treating sleep disorders using desloratadine
09/05/2000US6114345 Phenylsubstituted 4-azasteroid fluoroderivatives
09/05/2000US6114338 Heterocyclic compounds
09/05/2000US6114333 2-Pyrimidineamine derivatives and processes for their preparation
09/05/2000US6114329 5-HT4 receptor antagonists useful in the treatment of gastroinstestinal, cardiovascular and CNS disorders
09/05/2000US6114328 Isoxazoline and isoxazole fibrogen receptor antagonists
09/05/2000US6114326 Sleep disorders
09/05/2000US6114311 Administering an adenviral compound
09/05/2000US6114304 Administering an amylin agonist such as pramlintide or pramlintide acetate; reducing gastric motility or delaying gastric emptying
09/05/2000US6113947 Controlled release microencapsulated NGF formulation
09/05/2000US6113629 Hydrogel for the therapeutic treatment of aneurysms
09/05/2000CA2047686C Dietary supplement for insulin-resistant diabetics
09/05/2000CA2047685C Purified insulin mediators and purification process for same
09/05/2000CA1341093C Method and composition for preventing surgical adhesions
08/2000
08/31/2000WO2000050590A1 Mdm interacting protein and methods of use thereof
08/31/2000WO2000050453A1 A novel inhibitor of programmed cell death
08/31/2000WO2000050434A1 Malto-oligosaccharide derivatives and uses thereof
08/31/2000WO2000050429A1 Drugs containing phosphoric acid derivatives as the active ingredient
08/31/2000WO2000050420A1 6-substituted-7- heteroquinoxaline carboxylic acid derivatives and addition salts thereof and processes for the preparation of both
08/31/2000WO2000050416A1 6-substituted heteroquinolinecarboxylic acid derivatives and addition salts thereof and processes for the preparation of both
08/31/2000WO2000050400A1 2-aminopyridines containing fused ring substituents
08/31/2000WO2000050395A1 Sulfonamide-containing indole compounds
08/31/2000WO2000050062A2 Methods and compositions for altering mucus secretion
08/31/2000WO2000050046A1 Stabilized oral pharmaceutical composition containing iodide and iodate and method
08/31/2000WO2000050025A1 Topic tricyclic antidepressants as analgesics
08/31/2000WO2000049937A2 Trpm-2 antisense therapy
08/31/2000WO2000036113A3 Extending graft survival by heme oxygenase-i expression induced immunomodulation
08/31/2000WO2000033667A3 Bioflavonoids, anthocyanins and phenol compounds from cherries as antioxidants
08/31/2000WO2000027196A8 Use of gm-csf to inhibit development of drug resistance in hiv+ patients
08/31/2000WO2000019200A9 Identifying agents that alter mitochondrial permeability transition pores
08/31/2000WO2000018923A9 Slgp protein and nucleic acid molecule and uses therefor
08/31/2000WO2000012507A3 Pyrrolobenzodiazepines
08/31/2000WO2000012074A3 Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase
08/31/2000WO2000001375A3 Calcium channel blockers
08/31/2000DE10008042A1 Neurokinin-1-Rezeptorantagonisten Neurokinin-1 receptor antagonists
08/31/2000CA2850318A1 Trpm-2 antisense therapy
08/31/2000CA2371814A1 Trpm-2 antisense therapy
08/31/2000CA2366951A1 Methods and compositions for altering mucus secretion
08/31/2000CA2364754A1 6-substituted heteroquinolinecarboxylic acid derivatives and addition salts thereof and processes for the preparation of both
08/31/2000CA2364749A1 6-substituted-7-heteroquinoxaline carboxylic acid derivatives and addition salts thereof and processes for the preparation of both
08/31/2000CA2363621A1 A novel inhibitor of programmed cell death
08/31/2000CA2363106A1 Mdm interacting protein and methods of use thereof
08/31/2000CA2362564A1 Topic tricyclic antidepressants as analgesics
08/30/2000EP1031347A1 Transnasal transport/immunisation with highly adaptable carriers
08/30/2000EP1031343A1 Ready-to-use aqueous composition for bleaching of hair, containing a water soluble solvent and a non-ionic amphiphilic or anionic polymer with at least one fatty chain
08/30/2000EP1030935A1 Antisense oligonucleotide modulation of human serine/threonine protein phosphatase gene expression
08/30/2000EP1030929A1 Transfection and transfer of male germ cells for generation of transgenic species
08/30/2000EP1030918A2 Slit polypeptide and method of modulation of robo with ligands
08/30/2000EP1030917A1 Transcriptionally regulated g protein-coupled receptor
08/30/2000EP1030859A1 Ras-binding protein (pre1)
08/30/2000EP1030857A2 Adenosine a1 receptor agonists
08/30/2000EP1030856A2 Adenosine a1 receptor agonists
08/30/2000EP1030851A1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
08/30/2000EP1030845A1 Heterocyclic compounds having mmp and tnf inhibitory activity
08/30/2000EP1030840A1 Cyclic amine derivatives and their use as drugs
08/30/2000EP1030839A1 Use of alkylated iminosugars to treat multidrug resistance
08/30/2000EP1030836A1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
08/30/2000EP1030834A1 Benzocycloheptene derivatives
08/30/2000EP1030686A2 Lyophilizate of lipid complex of water insoluble porphyrins
08/30/2000EP1030683A1 Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions
08/30/2000EP1030681A1 Method and compositions for inhibiting angiogenesis and treating cancer
08/30/2000EP1030679A1 Compositions and methods for promoting internalization and degradation of urokinase-type plasminogen activator
08/30/2000EP1030670A1 Use of vitamin d derivatives to enhance efficacy of cytotoxic agents
08/30/2000EP1030667A1 Use of mirtazapine for treating sleep apneas
08/30/2000EP1030662A2 Treatment of t-helper cell type 2 mediated immune diseases with retinoid antagonists
08/30/2000EP1030661A1 N,N-DIETHYLGLYCOLAMIDO ESTER PRODRUGS OF INDOLE sPLA 2? INHIBITORS
08/30/2000EP0998251A4 Compositions and methods for inhibiting photoaging of skin
08/30/2000EP0836606B1 Condensed thiazole derivatives, having 5-ht receptor affinity
08/30/2000EP0799198B1 Anti-inflammatory compounds
08/30/2000EP0765328B1 Pirydyl imidazole derivatives and processes for the preparation thereof
08/30/2000EP0690843B1 Formyl- or cyano- substituted indole derivatives having dopaminergic activity
1 ... 1132 1133 1134 1135 1136 1137 1138 1139 1140 1141 1142 1143 1144 1145 1146 1147 1148 1149 1150 1151 1152 ... 1564